How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Surgical Treatment of Dermatophytosis Market
- By Treatment Modality: Surgical Excision, Laser Therapy, Cryosurgery, Electrosurgery, Mohs Micrographic Surgery
- By Indication: Onychomycosis, Tinea Corporis, Tinea Pedis, Tinea Capitis, Tinea Cruris
- By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients
- By Healthcare Setting: Hospitals, Specialty Dermatology Clinics, Outpatient Surgical Centers
- By Surgical Technique: Conventional Surgery, Minimally Invasive Surgery, Image-Guided Surgery
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Surgical Excision leads By Treatment Modality at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 293 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.177 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.185 →
Full report · locked preview
Everything inside the Surgical Treatment of Dermatophytosis Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Treatment Modality 5
Indication 5
Patient Demographics 3
Healthcare Setting 3
Surgical Technique 3
Companies profiled
Bausch Health
Galderma S.A.
Novartis AG
Pfizer Inc.
Moberg Pharma AB
Bayer AG
Dr. Reddy’s Laboratories Ltd.
Cipla Ltd.
Medimetriks Pharmaceuticals Inc.
Sanofi S.A.
GlaxoSmithKline Plc.
Teva Pharmaceutical industries Ltd.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Bausch Health
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Galderma S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Moberg Pharma AB
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Dr. Reddy’s Laboratories Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Cipla Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Medimetriks Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sanofi S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →GlaxoSmithKline Plc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Teva Pharmaceutical industries Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Cardinal Health Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Viatris Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Almirall
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →S.A
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,430M by 2033 · 7.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Surgical Excision49.5
- Laser Therapy7.9
- Cryosurgery19.6
- Electrosurgery8.8
- Mohs Micrographic Surgery14.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$268.3M → $490.2M · 7.8%
Europe$187.0M → $306.9M · 6.4%
Asia Pacific$170.7M → $286.6M · 6.7%
Latin America$105.7M → $200.8M · 8.4%
Middle East and Africa$81.3M → $127.6M · 5.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.282026
7.282027
7.302028
7.312029
7.312030
7.332031
7.342032
7.342033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Bausch Health22.7
- Galderma S.A.14.8
- Novartis AG9.2
- Pfizer Inc.4.7
- Moberg Pharma AB10.9
- Bayer AG9.8
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Modality24.7%
Indication9.9%
Patient Demographics16.1%
Healthcare Setting29.1%
Surgical Technique20.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.7
- Europe21.7
- Asia Pacific20.3
- Latin America14.2
- Middle East and Africa9.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Bausch Health | 98 | 93 | 91 | 96 | 80 | 78 | 89 |
| Galderma S.A. | 90 | 82 | 88 | 75 | 76 | 90 | 84 |
| Novartis AG | 77 | 71 | 67 | 85 | 86 | 73 | 77 |
| Pfizer Inc. | 75 | 82 | 61 | 80 | 77 | 57 | 72 |
| Moberg Pharma AB | 69 | 60 | 73 | 70 | 63 | 73 | 68 |
| Bayer AG | 57 | 54 | 63 | 50 | 46 | 69 | 57 |
| Dr. Reddy’s Laboratories Ltd. | 59 | 47 | 41 | 47 | 43 | 57 | 49 |
| Cipla Ltd. | 47 | 60 | 57 | 41 | 51 | 45 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Bausch Health
- Galderma S.A.
- Novartis AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Bausch Health | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Galderma S.A. | ✓ | ◐ | ✓ | ◐ | ✓ | ◐ |
| Novartis AG | ◐ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Pfizer Inc. | ✓ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Moberg Pharma AB | ◐ | − | − | ✓ | ◐ | ✓ |
| Bayer AG | − | ◐ | ◐ | ◐ | − | ◐ |
| Dr. Reddy’s Laboratories Ltd. | ◐ | − | − | − | − | − |
| Cipla Ltd. | − | − | − | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Bausch Health89
2Galderma S.A.84
3Novartis AG77
4Pfizer Inc.72
5Moberg Pharma AB68
6Bayer AG57
7Cipla Ltd.50
8Dr. Reddy’s Laboratories Ltd.49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Bausch HealthGalderma S.A.
Challenger3
Strong scale, closing on the leaders.
Novartis AGPfizer Inc.Moberg Pharma AB
Contender1
Focused players with pockets of strength.
Bayer AG
Niche2
Specialists in a single segment or region.
Dr. Reddy’s Laboratories Ltd.Cipla Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Modality in North America, then scale across Surgical Treatment of Dermatophytosis Market — a $357M beachhead inside a $6.09B market.
Beachhead (SOM)$357Mobtainable near-term
Serviceable (SAM)$2.07Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Surgical Excision
Best fit — highest urgency & budget in Treatment Modality.
Economic buyer80 fit
Laser Therapy
Strong fit — clear ROI and a fast path to value.
End user67 fit
Cryosurgery
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Modality in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Indication & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Patient Demographics
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve23%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Modality leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Surgical Treatment of Dermatophytosis Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified20%
Evaluation12%
Closed-won7%
$15.9KCAC
$89KLTV
5.6:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Surgical Treatment of Dermatophytosis Market is a durable-growth opportunity — $7.99B by 2033, compounding at 9.9%.
TAM · 2025$3.75Btoday
TAM · 2033$7.99Bforecast
CAGR9.9%2027–2033
Cumulative$50.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.99BTotal addressable market
SAM$2.81BServiceable available market
SOM$509MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.9% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Modality.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Modality moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.99BLarge & growingTAM by 2033 at 9.9% CAGR
$2.81BServiceable nowreachable with today’s model
$509MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.23BBear6.5% CAGR
$7.99BBase9.9% CAGR
$10.2BBull13.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Indication optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Surgical Treatment of Dermatophytosis Market — a $13.2B market by 2033. Plan: grow share from 7.0% to 13.5%.
Market size · 2033$13.2Btotal addressable
Market CAGR11.3%2027–2033
Target share13.5%from 7.0% today
Revenue ambition$1.78Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.0% | 13.5% | Ahead |
| Revenue | $988M | $1.78B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 30.5% | 38.7% | At risk |
| Customer retention | 85.9% | 95.9% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Modality
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Indication capability
A defensible second engine — invest in Indication to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Modality share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Indication
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $216M capacity & capability investment
- Greenlight bolt-on M&A in Indication
- Authorise North America expansion plan
- Fund R&D program for Treatment Modality leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Surgical Treatment of Dermatophytosis Market conversation — a $10.7B market you can size, segment and defend in minutes.
Market size · 2033$10.7Btotal opportunity
Growth8.6%CAGR to 2033
Addressable buyers1,378+accounts in scope
Typical ROI4.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Modality
Goal Grow share in Treatment Modality
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.8×return on cost, year one
< 4 mopayback period
$89K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Bausch HealthGalderma S.A.Novartis AGPfizer Inc.Moberg Pharma ABBayer AGDr. Reddy’s Laboratories Ltd.Cipla Ltd.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Surgical Treatment of Dermatophytosis Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Surgical Treatment of Dermatophytosis Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Surgical Treatment for Pelvic Prolapse Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportSurgical Tray Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportSurgical Torque Limiter Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportSurgical Topical Absorbable Hemostat Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportSurgical Thoracic Trocar Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportSurgical Thimbles Market
Market size, share, segmentation and regional forecast.
$355M market · 2025 base year
View reportSurgical Table System Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportSurgical Tables and Lights Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportSurgical Table Headrests Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportSurgical Suture Needles Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportSurgical Suture Needle and Thread Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportSurgical Support Arms Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.